Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Pediatric Hematology

Why Do Beta-Thalassemia Symptoms Start at 3-6 Months?

At a Glance

Babies with beta-thalassemia major appear healthy at birth because they are protected by fetal hemoglobin. Symptoms of severe anemia appear at 3 to 6 months of age when the body naturally switches to adult hemoglobin, which their body cannot properly produce.

It is completely normal to be confused or overwhelmed when your baby, who seemed perfectly healthy at birth, begins showing signs of severe anemia a few months later. The delayed onset of beta-thalassemia major symptoms is due to a natural process every baby goes through: the transition from producing fetal hemoglobin to adult hemoglobin [1]. At birth, your baby’s blood is rich in fetal hemoglobin, which works perfectly fine and keeps them healthy. However, as they reach 3 to 6 months of age, their body naturally stops making fetal hemoglobin and tries to switch to adult hemoglobin [2][1]. Because beta-thalassemia major prevents the body from making functional adult hemoglobin, the drop in fetal hemoglobin leaves the baby without enough healthy red blood cells, causing symptoms of anemia to suddenly appear [3].

Quick Timeline: The Hemoglobin Transition

  • Birth to 3 months: Protected by high levels of healthy fetal hemoglobin. Baby appears completely healthy.
  • 3 to 6 months: The natural “hemoglobin switch” begins. Fetal hemoglobin drops, and the body tries to make adult hemoglobin.
  • 6+ months: The lack of functional adult hemoglobin leads to severe anemia, and symptoms become noticeable.

The Protective Power of Fetal Hemoglobin at Birth

Hemoglobin is the protein in red blood cells that carries oxygen from the lungs to the rest of the body. While in the womb, and for the first few months of life, babies rely on a special type of hemoglobin called fetal hemoglobin (HbF) [1].

Fetal hemoglobin is made up of two types of building blocks: alpha-globin and gamma-globin [1]. Notice that it does not use beta-globin. Because beta-thalassemia major is a genetic condition that specifically affects the production of beta-globin, it does not impact fetal hemoglobin [4][1]. This means that at birth, your baby has plenty of perfectly healthy, functional fetal hemoglobin. This is why newborns with beta-thalassemia major appear completely healthy and do not show any symptoms of the condition [3].

The Hemoglobin Switch

In all infants, a natural biological “switch” occurs shortly after birth. The body begins to silence the genes that make fetal hemoglobin (gamma-globin) and turns on the genes that make adult hemoglobin (beta-globin) [1][5].

By the time a baby is between 3 and 6 months old, the majority of their fetal hemoglobin has been replaced by adult hemoglobin [2][1]. In a baby without beta-thalassemia, this transition is seamless. Their body produces healthy adult hemoglobin (known as HbA), and they continue to grow and thrive.

What Happens in Beta-Thalassemia Major

For babies with beta-thalassemia major, this hemoglobin switch reveals the underlying genetic condition. The condition is caused by mutations in the HBB gene—the genetic instructions for making beta-globin [4]. This means the body is either unable to produce beta-globin or produces very little of it [6].

As the protective fetal hemoglobin levels naturally drop, the body tries to make adult hemoglobin to replace it. However, because the beta-globin building blocks are missing or defective, the body cannot form complete, working adult hemoglobin [3][7]. This leads to two main problems:

  • Severe Anemia: Without enough healthy hemoglobin, red blood cells cannot carry enough oxygen to the body’s tissues. This causes the classic symptoms of anemia, such as pale skin, extreme fatigue, fussiness, and poor feeding [3].
  • Red Blood Cell Damage: Because the alpha-globin building blocks don’t have beta-globin partners to pair up with, they build up inside the developing red blood cells [3][8]. This buildup damages the cells, causing them to break down prematurely before they can even leave the bone marrow [9][10].

To compensate for the lack of healthy red blood cells, the body may try to produce blood outside of the bone marrow, such as in the liver or spleen. If the anemia is not treated, this can cause these organs to swell (a condition called hepatosplenomegaly) [11][12]. Fortunately, starting a regular blood transfusion schedule effectively treats the anemia, which stops this overworking of the organs and prevents or reverses the swelling [11].

Moving Forward

Understanding this transition can help make sense of the sudden diagnosis. Your baby did not “catch” the condition at 6 months old; rather, their natural fetal hemoglobin protected them until the physiological switch occurred [1][3].

Because your baby’s body cannot produce enough adult hemoglobin on its own, they will need lifelong care to manage the anemia and support their growth. Your care team will guide you through the next steps, which typically involve a regular schedule of blood transfusions to provide the healthy red blood cells your baby needs [3][11]. Because these life-saving transfusions bring extra iron into the body over time, your medical team will eventually introduce daily medication (called iron chelation therapy) to safely remove the excess iron and protect your baby’s organs.

While a lifelong diagnosis is daunting, children with beta-thalassemia major who receive appropriate transfusion and chelation therapy can grow, thrive, and live full lives. You will work closely with a hematologist to establish this routine and discuss long-term options, including potential curative treatments like bone marrow transplants.

Common questions in this guide

Why did my baby seem completely healthy at birth if they have beta-thalassemia major?
At birth, babies rely on a special type of blood protein called fetal hemoglobin. Because beta-thalassemia major specifically affects the production of adult hemoglobin, your baby's fetal hemoglobin functions perfectly and keeps them healthy during their first few months.
What is the hemoglobin switch?
Between 3 and 6 months of age, all babies naturally stop making fetal hemoglobin and try to switch over to making adult hemoglobin. In beta-thalassemia major, the body lacks the genetic instructions to make functional adult hemoglobin, which causes severe anemia as the fetal hemoglobin drops.
What are the signs of severe anemia in a baby with beta-thalassemia major?
Without enough healthy red blood cells to carry oxygen, your baby may experience extreme fatigue, pale skin, fussiness, and poor feeding. You may also notice a swollen belly, which happens if the liver or spleen becomes enlarged trying to compensate for the anemia.
How will my baby's anemia be treated once the fetal hemoglobin drops?
The primary treatment is a regular schedule of blood transfusions to provide the healthy adult red blood cells your baby's body cannot make. Because these transfusions introduce extra iron, your care team will eventually prescribe daily iron chelation therapy to safely remove it.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my baby's current hemoglobin level, and how often will we need to check it?
  2. 2.When should we expect to start regular blood transfusions, and what does that schedule typically look like for an infant?
  3. 3.When will we need to start monitoring my baby's iron levels, and what does iron chelation therapy involve?
  4. 4.What specific signs or symptoms should prompt me to bring my baby to the hospital or call the clinic between scheduled visits?
  5. 5.Has my baby's swollen belly (enlarged liver or spleen) been evaluated, and what changes should we expect to see once transfusions begin?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    A Review of Gene Therapies for Hemoglobinopathies.

    Jones-Wonni B, Kelkar AH, Achebe MO

    Hemoglobin 2024; (48(3)):141-152 doi:10.1080/03630269.2024.2369534.

    PMID: 39145521
  2. 2

    Regulation of the fetal hemoglobin silencing factor BCL11A.

    Basak A, Sankaran VG

    Annals of the New York Academy of Sciences 2016; (1368(1)):25-30 doi:10.1111/nyas.13024.

    PMID: 26963603
  3. 3

    Thalassemia.

    Merkeley H, Bolster L

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2020; (192(41)):E1210 doi:10.1503/cmaj.191613.

    PMID: 33051316
  4. 4

    Genotype Distribution and Clinical Characteristics of Thalassemia Patients Needing Transfusion in Yangjiang, Western Guangdong.

    Chen ZX, Liu RH, Huang JC, et al.

    Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2025; (52(3)):202-210 doi:10.1159/000540518.

    PMID: 40485898
  5. 5

    MBD2a-NuRD binds to the methylated γ-globin gene promoter and uniquely forms a complex required for silencing of HbF expression.

    Shang S, Li X, Azzo A, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2023; (120(25)):e2302254120 doi:10.1073/pnas.2302254120.

    PMID: 37307480
  6. 6

    Genotype-phenotype correlation among beta-thalassemia and beta-thalassemia/HbE disease in Thai children: predictable clinical spectrum using genotypic analysis.

    Traivaree C, Monsereenusorn C, Rujkijyanont P, et al.

    Journal of blood medicine 2018; (9()):35-41 doi:10.2147/JBM.S159295.

    PMID: 29695942
  7. 7

    Pregnancy and Childbirth: An Unexpected Cakewalk for a Mother With Beta Thalassemia Major Homozygous for IVS (G-C) Mutation.

    Ghosh MD, Datta MR, Singh V, Rana F

    Cureus 2021; (13(3)):e13872 doi:10.7759/cureus.13872.

    PMID: 33868836
  8. 8

    A Genetic Variant Ameliorates β-Thalassemia Severity by Epigenetic-Mediated Elevation of Human Fetal Hemoglobin Expression.

    Chen D, Zuo Y, Zhang X, et al.

    American journal of human genetics 2017; (101(1)):130-138 doi:10.1016/j.ajhg.2017.05.012.

    PMID: 28669403
  9. 9

    Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.

    Richard F, van Lier JJ, Roubert B, et al.

    American journal of hematology 2020; (95(1)):68-77 doi:10.1002/ajh.25670.

    PMID: 31674058
  10. 10

    Innovative Treatments for Rare Anemias.

    Cappellini MD, Marcon A, Fattizzo B, Motta I

    HemaSphere 2021; (5(6)):e576 doi:10.1097/HS9.0000000000000576.

    PMID: 34095760
  11. 11

    Achievement of Pre- and Post-Transfusion Hemoglobin Levels in Adult Transfusion-Dependent Beta Thalassemia: Associated Factors and Relationship to Reduction of Spleen Enlargement.

    Atmakusuma TD, Saragih EYP, Rajabto W

    International journal of general medicine 2021; (14()):7515-7521 doi:10.2147/IJGM.S338114.

    PMID: 34754224
  12. 12

    An Unusual Presentation of a Patient with Leg Ulcers: A Case Report.

    Zafar S, Saleem K, Rashid A

    Cureus 2019; (11(12)):e6293 doi:10.7759/cureus.6293.

    PMID: 31938587

This page provides educational information about the onset of beta-thalassemia major symptoms in infants. It is not a substitute for professional medical advice, diagnosis, or treatment from your pediatric hematologist.

Get notified when new evidence is published on Beta-thalassemia major.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.